| DC8908 |
Darunavir ethanolate
Featured
|
Darunavir ethanolate is an HIV protease inhibitor,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC12498 |
S-Darusentan
Featured
|
Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteries. |
|
| DC8647 |
DASA-58
Featured
|
DASA-58 is a highly specific small molecule PKM2 activator. DASA-58 inhibits LPS-induced Hif-1a and IL-1b, as well as the expression of a range of other Hif-1a-dependent genes. |
|
| DC2100 |
Dasatinib (BMS-354825)
Featured
|
Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of ＜1 nM, 0.5 nM and 79 nM, respectively. |
|
| DC3140 |
Dasatinib monohydrate
Featured
|
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. |
|
| DC10073 |
Dasotraline Hydrochloride
Featured
|
Dasotraline is a stereoisomer of desmethylsertraline, which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft) and an SNDRI similarly. |
|
| DC8162 |
Dasotraline(SEP-225289) free base
Featured
|
Dasotraline(SEP-225289) is a triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters with IC50 values of 4, 6, and 11 nM, respectively. |
|
| DC20229 |
Datelliptium chloride
Featured
|
Datelliptium chloride is a DNA-intercalating agent derived from ellipticine, with anti-tumor activities. |
|
| DC7069 |
Daunorubicin HCL
Featured
|
Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM. |
|
| DC25058 |
Daunorubicin
Featured
|
Daunorubicin is potent topoisomerase II (Topo II) inhibitor, interacts with DNA by intercalation and inhibition of macromolecular biosynthesis in cancer cells. |
|
| DC8826 |
DB07268
Featured
|
DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM. |
|
| DC23251 |
DB213
Featured
|
DB213 (RG-501) is a small molecule stimulator of HIV-1 frameshifting and inhibitor of viral replication. |
|
| DC22069 |
DB818
Featured
|
DB818 (DB-818, DB 818) is a small molecule inhibitor of HOXA9/DNA interaction through binding as minor groove DNA ligand on the HOXA9 cognate sequence. |
|
| DC21890 |
DBCO intermidate 3
Featured
|
DBCO intermidate 3 is a Click Chemistry intermidate used for antibody-drug conjugates.. |
|
| DC7602 |
DBeQ
Featured
|
DBeQ is a selective, potent, reversible, and ATP-competitive p97 inhibitor with IC50 of 1.5 μM. |
|
| DC12023 |
dBET1
Featured
|
dBET1 is a potent BRD4 protein degrader based on PROTAC technology with an EC50 of 430 nM. |
|
| DC21893 |
dBET57
Featured
|
dBET57 is a novel BRD4 heterobifunctional small-molecule ligand (PROTAC), exhibits significant and selective degradation of BRD4 BD1 (DC50/5h=500 nM), but is inactive on BRD4 BD2.. |
|
| DC12022 |
dBET6
Featured
|
dBET6 is a highly potent, selective and cell-permeable degrader of BET with an IC50 of 14 nM, and has antitumor activity. |
|
| DC12665 |
DBPR114
Featured
|
DBPR114 is a quinazoline-based multi-kinase inhibitor for the treatment of acute myeloid leukemia and other solid tumors. |
|
| DC7790 |
CB1-IN-1(BPRCB1184)
Featured
|
CB1-IN-1 (BPRCB1184) is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively. IC50 value: 0.3 nM (Ki, CB1R) 21 nM (Ki, CB2R) Target: CB1R in vivo: CB1-IN-1 is a novel peripherally restricted cannabinoid 1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice. CB1-IN-1 has great potential to ameliorate this related metabolic syndrome. |
|
| DC11589 |
dBRD9
Featured
|
dBRD9 is a PROTAC that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex. |
|
| DC23977 |
DC-05
Featured
|
DC-05 is a selective, non-nucleoside DNA methyltransferase DNMT1 inhibitor with IC50 of 10.3 uM, displays 3.6-fold selectivity over PRMT1 and >15-fold over DNMT3A, DNMT3B, G9a, SUV39H1, MLL1, SET7/9.. |
|
| DC20945 |
DC_AC50
Featured
|
DC_AC50 (DCAC50) is a small molecule that inhibits the human copper chaperones Atox1 and CCS (Kd=6.8 and 8.2 uM), blocks copper trafficking and significantly attenuates cancer cell proliferation. |
|
| DC10554 |
DC260126
Featured
|
DC260126, a small-molecule antagonist of GPR40. |
|
| DC12554 |
DC661
Featured
|
DC661 (DC-661) is a novel dimeric chloroquine (CQ) that is capable of deacidifying the lysosome and inhibiting autophagy significantly better than HCQ, targets palmitoyl-protein thioesterase 1 (PPT1). |
|
| DC5041 |
DCC-2036 (Rebastinib)
Featured
|
DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2. |
|
| DC9585 |
c-Kit-IN-1(DCC-2618)
Featured
|
DCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFRα/PDGFRβ respectively. |
|
| DC20175 |
Ripretinib (DCC-2618)
Featured
|
DCC-2618 is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and PDGFR-alpha, with IC50 values of 4 nM, 8 nM, 18 nM, 5 nM and 14 nM. |
|
| DC20947 |
DDD 85646
Featured
|
DDD 85646 is a potent, specific, dual N-Myristoyltransferase NMT1/NMT2 inhibitor with IC50 of 17 nM/22 nM respectively. |
|
| DC10996 |
DDR inhibitor X
Featured
|
DDR inhibitor X is a potent discoidin domain receptor (DDR) inhibitor with IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.. |
|
